Clinical trials: Antipsychotic Agents
Insulin Resistance, Dyslipidemia
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans
We hypothesized that short-term treatment with AP drugs induces insulin resistance through a mechanistic route that is independent of weight gain and that atypical drugs exert stronger effects than typical compounds in this…
- Trial name
- NCT00625170
- Testing
- olanzapine, Haloperidol
- Where
- Netherlands
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Patient Noncompliance
Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic
Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%.
- Trial name
- CAE-L (NCT01152697)
- Testing
- haloperidol decanoate, haloperidol, Customized Adherence Enhancement
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia
The Phase I Study of HS-10509 in Chinese Adult Subjects
The study is to evaluate the safety, tolerability, and PK characteristics following single administration of HS-10509 in healthy adults, and multiple administrations of HS-10509 in patients with schizophrenia.
- Trial name
- NCT06301074
- Testing
- HS-10509
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Schizophrenia, Schizoaffective Disorder
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery disease (CAD) risk and illness…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder
- Trial name
- CAD (NCT00167310)
- Testing
- Eicosapentaenoic acid (omega-3 fatty acid)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Pittsburgh
Cognitive Impairment Associated With Schizophrenia
Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia
To establish the proof of concept that MEM 3454, used as add-on pharmacotherapy, is a safe and effective treatment in patients with cognitive impairment associated with schizophrenia (CIAS).
- Trial name
- NCT00604760
- Testing
- MEM 3454
- Where
- 44 sites in United States
- Volunteers
- 160 people
- Sponsor
- Memory Pharmaceuticals
Schizophrenia
Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia
In a population of patients suffering from schizophrenia being treated for an episode of clinical destabilization and followed for a period of twelve months, the main objective is to evaluate the proportion of patients achieving…
- Trial name
- NCT02874560
- Where
- France
- Volunteers
- 364 people
- Sponsor
- Janssen-Cilag Ltd.
Obesity, Weight Gain
Reducing Antipsychotic-Induced Weight Gain in Children With Metformin
Recent but limited short term studies have shown that Metformin can slow down weight gain in obese children and in children with psychotropic-induced weight gain, two distinct pediatric populations that are at risk for obesity…
- Conditions
- Obesity, Weight Gain, Psychotropic Induced Weight Gain
- Trial name
- GFMS (NCT01231074)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Nationwide Children's Hospital
Diabetes
Examining the Effects of Antipsychotic Medications on Insulin Sensitivity
This study will examine the effects of two different antipsychotic medications on control of blood sugar in people who are at risk of diabetes but mentally healthy.
- Trial name
- NCT00895921
- Testing
- Olanzapine, Aripiprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Bipolar I Disorder
Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients
The purpose of this study is to determine whether Bipolar I Disorder refractory treatment with Quetiapine monotherapy could be better potentiated with Lithium or Aripiprazole.
- Trial name
- ARIQUELI (NCT01710163)
- Testing
- Lithium, Aripiprazole
- Where
- 2 sites in Brazil
- Volunteers
- 50 people
- Sponsor
- University of Sao Paulo
Schizophrenia
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
This study will determine the efficacy and safety of RO4917838 in patients with schizophrenia who are stable on current antipsychotic treatment (olanzapine, que tiapine, risperidone, paliperidone or aripiprazole) with prominent…
- Trial name
- NCT00616798
- Testing
- RO4917838, Standard antipsychotic therapy
- Where
- 73 sites in United States, Austria and 8 more
- Volunteers
- 323 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Conditions
- Schizophrenia, Psychotic Disorders, Psychosis
- Trial name
- PAFIP3_nc3Y (NCT03883204)
- Testing
- Aripiprazole, Risperidone
- Where
- Spain
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Weight Gain
Effects of Modafinil on Olanzapine Weight Gain
This study is designed as a 3 week, randomized, double blind, placebo controlled, trial. Olanzapine and modafinil will be titrated to 10mg and 200mg respectively.
- Trial name
- NCT00636896
- Testing
- Olanzapine plus modafinil
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neuropsychiatric Research Institute, Fargo, North Dakota
Schizophrenia
Schizophrenia Sensory Gating Deficit With Quetiapine
The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to…
- Trial name
- NCT00536783
- Testing
- Quetiapine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- New Mexico VA Healthcare System
Schizophrenia, Diabetes
Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism
Patients suffering from schizophrenia have a high risk to become obese and develop diabetes. Risk of obesity is particularly high with some newer schizophrenia drugs, such as clozapine or olanzapine.
- Conditions
- Schizophrenia, Diabetes, Insulin Resistance
- Trial name
- NCT01160991
- Testing
- Glucose clamp technique, Amisulpride, Olanzapine
- Where
- Germany
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Functional Dyspepsia
Effect of Amitriptyline and Trifluoperazine on Patients With Functional Dyspepsia
The goal of this clinical trial is to assess and compare the effect of amitriptyline and trifluoperazine in improving dyspeptic symptoms in patients with functional dyspepsia.
- Trial name
- NCT07008235
- Testing
- Tablet Amitriptyline 10 milligrams, Tablet Trifluoperazine 1 milligrams twice daily, Standard First-Line Therapy
- Where
- Bangladesh
- Volunteers
- 120 people
- Sponsor
- Md. Moktadirul Hoque Shuvo
Schizophrenia
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
- Trial name
- CONVOKE (NCT05838625)
- Testing
- CT-155, Digital Control
- Where
- 54 sites in United States
- Volunteers
- 464 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia
Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain
This is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated on AOM treatment during an schizophrenia-related hospitalisation at least 6 months before data…
- Trial name
- PROSIGO (NCT03130478)
- Where
- 15 sites in Spain
- Volunteers
- 119 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Schizophrenia, Hepatic Impairment
A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function
The purpose of this study is 1) to investigate the single-dose pharmacokinetics of immediate release (IR) paliperidone, after oral administration, in patients having moderate hepatic impairment compared to patients having normal…
- Trial name
- NCT00791284
- Testing
- Intermediate release (IR) Paliperidone
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia
The purpose of this study is to compare the effectiveness and safety over 1 year of treatment of intramuscular injections of paliperidone palmitate and long-acting risperidone in patients with schizophrenia.
- Trial name
- NCT00210717
- Testing
- paliperidone palmitate
- Volunteers
- 748 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes, Obesity
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2
This program aims to help Veterans who take antipsychotic medications lose weight. We use a program based on the American Diabetes Association's "Diabetes Prevention Program," and we have modified it to fit the lifestyles of…
- Conditions
- Diabetes, Obesity, Weight Gain
- Trial name
- MAMAO2 (NCT01052714)
- Testing
- Lifestyle Balance
- Where
- 3 sites in United States
- Volunteers
- 121 people
- Sponsor
- VA Office of Research and Development